502 related articles for article (PubMed ID: 12489924)
1. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
2. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
Grandjean F; Brémaud L; Verdier M; Robert J; Ratinaud MH
Anticancer Drugs; 2001 Mar; 12(3):247-58. PubMed ID: 11290872
[TBL] [Abstract][Full Text] [Related]
3. Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.
Tkaczyk-Gobis K; Tarasiuk J; Seksek O; Stefanska B; Borowski E; Garnier-Suillerot A
Eur J Pharmacol; 2001 Feb; 413(2-3):131-41. PubMed ID: 11226386
[TBL] [Abstract][Full Text] [Related]
4. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
5. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
Gu J; Fang X; Hao J; Sha X
Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
[TBL] [Abstract][Full Text] [Related]
6. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca
Sun Y; Wang C; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Peng J; Liu K
J Cell Physiol; 2018 Apr; 233(4):3066-3079. PubMed ID: 28681913
[TBL] [Abstract][Full Text] [Related]
7. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
8. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line.
Li J; Xu LZ; He KL; Guo WJ; Zheng YH; Xia P; Chen Y
Breast Cancer Res; 2001; 3(4):253-63. PubMed ID: 11434876
[TBL] [Abstract][Full Text] [Related]
9. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
Chao CC
FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
[TBL] [Abstract][Full Text] [Related]
10. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
11. A Novel Drug Modulator Diarylheptanoid (
Viriyaadhammaa N; Duangmano S; Saiai A; Tungjai M; Dejkriengkraikul P; Tima S; Chiampanichayakul S; Krise J; Anuchapreeda S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012254
[No Abstract] [Full Text] [Related]
12. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.
Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K
Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.
Uchiyama-Kokubu N; Watanabe T
Anticancer Drugs; 2001 Oct; 12(9):769-79. PubMed ID: 11593059
[TBL] [Abstract][Full Text] [Related]
16. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells.
Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z
Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231
[TBL] [Abstract][Full Text] [Related]
17. [Reversal effect of berbamine on multidrug resistance of K562/A02 cells and its mechanism].
Han YQ; Yuan JY; Shi YJ; Zhu Y; Wu SL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):604-8. PubMed ID: 14706144
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells.
Chen BA; Mao PP; Cheng J; Gao F; Xia GH; Xu WL; Shen HL; Ding JH; Gao C; Sun Q; Chen WJ; Chen NN; Liu LJ; Li XM; Wang XM
Int J Nanomedicine; 2010 Aug; 5():437-44. PubMed ID: 20957165
[TBL] [Abstract][Full Text] [Related]
19. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
